Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.33 |
| ▸ | USP7 | Q93009 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | JAK1 | P23458 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24469914 | 0.97 | GPR119 (0.33) | GPR119USP7 | |
| SCHEMBL24470090 | 0.89 | GPR119 (0.32) | GPR119USP7JAK2JAK1MEN1 | |
| SCHEMBL24470113 | 0.89 | GPR119 (0.32) | GPR119USP7JAK2JAK1 | |
| SCHEMBL24469871 | 0.89 | ADAM17 (0.34) | GPR119KDM4EPKMMEN1CYP2C19 | |
| SCHEMBL24470117 | 0.85 | GPR119 (0.33) | GPR119USP7S1PR2 | |
| SCHEMBL24483802 | 0.83 | P2RX7 (0.31) | — | |
| SCHEMBL24483907 | 0.83 | — | — | |
| SCHEMBL24470075 | 0.83 | — | — | |
| SCHEMBL24483864 | 0.83 | — | — | |
| SCHEMBL24470104 | 0.82 | GPR119 (0.31) | GPR119USP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820773-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-20220169650-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2022-06-02 | — | — | US | disclosed |
| WO-2022115384-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. (US) | 2022-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169650-A1 | TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CEL | GPR119 1165/4885USP7 3629/4885KDM4E 4358/4885 |
| US-11820773-B2 | Tricyclic compounds | SLC10A1, PKD1, CEL | GPR119 1165/4885USP7 3629/4885KDM4E 4358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.